Maxim Group Releases a Buy Rating on Kintara Therapeutics (KTRA)

In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to Kintara Therapeutics (KTRAResearch Report), with a price target of $3.00. The company’s shares closed last Tuesday at $1.36.

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 29.3% and a 48.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.

Kintara Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.50, representing a 232.1% upside. In a report issued on September 14, Aegis Capital also initiated coverage with a Buy rating on the stock with a $6.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.95 and a one-year low of $0.38. Currently, Kintara Therapeutics has an average volume of 917.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.